Beam Therapeutics (BEAM) Long-Term Investments (2020 - 2021)

Beam Therapeutics (BEAM) reported Long-Term Investments of $24.5 million for Q3 2021, down 16.62% quarter-over-quarter from $29.4 million in Q2 2021.

Beam Therapeutics (BEAM) Long-Term Investments (2020 - 2021) Analysis & Trends

Beam Therapeutics (BEAM) has 2 years of Long-Term Investments data on file, last reported at $24.5 million in Q3 2021.

Long-Term Investments for Q3 2021 came in at $24.5 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2021 was $24.5 million (changed N/A YoY), and the FY2020 annual result was $2.6 million, changed N/A from the prior year.
Long-Term Investments slipped to $24.5 million in Q3 2021 per BEAM's latest filing, from $29.4 million in the prior quarter.
Over five years, Long-Term Investments peaked at $29.4 million in Q2 2021 and troughed at $2.6 million in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	5.17 Mn
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	5.75 Bn
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Beam Therapeutics	3.53 Bn	3.53 Bn	-	-

Download Data